The Quintiles Emerging Biopharma Solution is a newly developed operating model
Quintiles has announced the launch of its new solution set, 'Quintiles Emerging Biopharma Solution', a new offering designed to meet the unique clinical development needs and goals of bio-pharma companies.
"Emerging bio-pharmaceutical companies have been important Quintiles customers throughout our 30+ year history, and we understand the unique challenges they face. This new offering focuses squarely on those challenges-combining an operational model designed to meet these customers' needs with access to Quintiles' global infrastructure, integrated technology, and therapeutic expertise. It is a combination we believe will help provide superior delivery and improve the probability of success for this customer segment," said Ms Paula Brown Stafford, president, clinical development, Quintiles.
This new solution is a newly developed operating model that is aligned with the needs of the bio-pharmaceutical companies and leverages a company's integrated technology platform to provide them with real-time data access as well as a transparent view of project performance. It includes senior-level sponsorship for each company. This level of support provides easy access to the unique expertise and operational support required by these companies.